Five-year visual outcomes after anti-VEGF therapy with or without photodynamic therapy for polypoidal choroidal vasculopathy
- 6 June 2018
- journal article
- research article
- Published by BMJ in British Journal of Ophthalmology
- Vol. 103 (5) , 617-622
Abstract
Background/aims To evaluate the 5-year visual and anatomical outcomes after anti-vascular endothelial growth factor (VEGF) therapy alone or in combination with photodynamic therapy (PDT), followed by pro re nata (PRN) anti-VEGF therapy with or without PDT, for polypoidal choroidal vasculopathy (PCV). Methods This retrospective, observational study included 61 consecutive patients with treatment-naïve symptomatic PCV who were followed for 5 years. Twenty eyes (20 patients) initially received PDT and intravitreal injection of ranibizumab (IVR), followed by a PRN regimen of anti-VEGF therapy with or without PDT (combination group), while 41 eyes (41 patients) initially received only IVR every 3 months, followed by a PRN regimen of anti-VEGF monotherapy (IVR group). Macular atrophy including the fovea was confirmed using colour fundus photography and spectral-domain optical coherence tomography. Results In both groups, the visual acuity (VA) at 1 year was better than the baseline VA, whereas the 3-year, 4-year and 5-year VA values were similar to the baseline VA. There was no significant difference in the 5-year VA, 5-year central retinal thickness and incidence of macular atrophy between the two groups (p=0.63, 0.72 and 0.06, respectively). In the combination group, the 5-year VA was correlated with the 5-year incidence of macular atrophy (p=0.02, r=0.51). Conclusions A PRN regimen for PCV may have a limited effect for the long-term maintenance of improved VA. Macular atrophy may occur more frequently with combination therapy and is possibly associated with the 5-year VA. Thus, combination therapy should be carefully selected for patients susceptible to macular atrophy.Keywords
Funding Information
- Japan Society for the Promotion of Science (26861451)
- Ministry of Education, Culture, Sports, Science and Technology
This publication has 24 references indexed in Scilit:
- Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular DegenerationOphthalmology, 2012
- Treatment of Polypoidal Choroidal Vasculopathy With Photodynamic Therapy Combined With Intravitreal Injections of RanibizumabAmerican Journal of Ophthalmology, 2012
- INTRAVITREAL RANIBIZUMAB COMBINED WITH VERTEPORFIN PHOTODYNAMIC THERAPY FOR TREATING POLYPOIDAL CHOROIDAL VASCULOPATHYRetina, 2011
- Association of Lesion Size and Visual Prognosis to Polypoidal Choroidal VasculopathyAmerican Journal of Ophthalmology, 2011
- Polypoidal Choroidal Vasculopathy: A ReviewSurvey of Ophthalmology, 2010
- Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisationBritish Journal of Ophthalmology, 2009
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- GUIDELINES FOR USING VERTEPORFIN (VISUDYNE) IN PHOTODYNAMIC THERAPY FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION AND OTHER CAUSES: UPDATERetina, 2005
- Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathyBritish Journal of Ophthalmology, 2004
- IDIOPATHIC POLYPOIDAL CHOROIDAL VASCULOPATHY (IPCV)Retina, 1990